Roosevelt Investment Group Inc. decreased its position in shares of Edwards Lifesciences Corp (NYSE:EW) by 96.9% during the 4th quarter, HoldingsChannel reports. The fund owned 3,489 shares of the medical research company’s stock after selling 108,076 shares during the period. Roosevelt Investment Group Inc.’s holdings in Edwards Lifesciences were worth $393,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the business. Wells Fargo & Company MN boosted its position in Edwards Lifesciences by 20.2% in the third quarter. Wells Fargo & Company MN now owns 2,548,282 shares of the medical research company’s stock valued at $278,553,000 after buying an additional 429,022 shares in the last quarter. American Century Companies Inc. boosted its position in Edwards Lifesciences by 7.0% in the third quarter. American Century Companies Inc. now owns 2,224,010 shares of the medical research company’s stock valued at $243,107,000 after buying an additional 144,701 shares in the last quarter. Artisan Partners Limited Partnership boosted its position in Edwards Lifesciences by 12.0% in the third quarter. Artisan Partners Limited Partnership now owns 1,432,428 shares of the medical research company’s stock valued at $156,579,000 after buying an additional 153,896 shares in the last quarter. Legal & General Group Plc boosted its position in Edwards Lifesciences by 1.9% in the third quarter. Legal & General Group Plc now owns 1,118,298 shares of the medical research company’s stock valued at $122,217,000 after buying an additional 20,931 shares in the last quarter. Finally, Old Mutual Global Investors UK Ltd. boosted its position in Edwards Lifesciences by 83.0% in the third quarter. Old Mutual Global Investors UK Ltd. now owns 1,100,885 shares of the medical research company’s stock valued at $120,337,000 after buying an additional 499,436 shares in the last quarter. Hedge funds and other institutional investors own 81.11% of the company’s stock.

In related news, VP Robert W.A. Sellers sold 12,020 shares of Edwards Lifesciences stock in a transaction on Monday, February 5th. The shares were sold at an average price of $131.03, for a total transaction of $1,574,980.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 5,300 shares of Edwards Lifesciences stock in a transaction on Monday, January 29th. The stock was sold at an average price of $127.24, for a total transaction of $674,372.00. Following the transaction, the vice president now directly owns 24,908 shares of the company’s stock, valued at approximately $3,169,293.92. The disclosure for this sale can be found here. Insiders have sold 175,940 shares of company stock valued at $20,049,578 in the last ninety days. Insiders own 2.13% of the company’s stock.

A number of brokerages have weighed in on EW. Morgan Stanley raised their target price on shares of Edwards Lifesciences from $130.00 to $138.00 and gave the company an “overweight” rating in a research report on Friday, February 2nd. Barclays raised their target price on shares of Edwards Lifesciences from $135.00 to $155.00 and gave the company an “overweight” rating in a research report on Friday, February 2nd. JMP Securities raised their target price on shares of Edwards Lifesciences from $135.00 to $140.00 and gave the company a “market outperform” rating in a research report on Friday, February 2nd. Stifel Nicolaus restated a “buy” rating and issued a $155.00 target price on shares of Edwards Lifesciences in a research report on Friday, February 2nd. Finally, Guggenheim restated a “buy” rating and issued a $162.00 target price on shares of Edwards Lifesciences in a research report on Friday, February 2nd. Three investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $141.15.

Edwards Lifesciences Corp (NYSE:EW) opened at $126.89 on Tuesday. The stock has a market cap of $26,721.24, a price-to-earnings ratio of 44.06, a PEG ratio of 1.86 and a beta of 0.63. Edwards Lifesciences Corp has a 52 week low of $89.20 and a 52 week high of $138.48. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.41 and a current ratio of 1.81.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, February 1st. The medical research company reported $0.94 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.91 by $0.03. The firm had revenue of $888.50 million during the quarter, compared to the consensus estimate of $868.45 million. Edwards Lifesciences had a net margin of 18.11% and a return on equity of 27.69%. The company’s revenue for the quarter was up 15.7% on a year-over-year basis. During the same quarter last year, the firm earned $0.75 earnings per share. sell-side analysts forecast that Edwards Lifesciences Corp will post 4.49 EPS for the current fiscal year.

Edwards Lifesciences declared that its Board of Directors has authorized a share repurchase program on Thursday, December 7th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the medical research company to buy shares of its stock through open market purchases. Shares buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.

WARNING: “Roosevelt Investment Group Inc. Has $393,000 Position in Edwards Lifesciences Corp (EW)” was first posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.watchlistnews.com/roosevelt-investment-group-inc-has-393000-position-in-edwards-lifesciences-corp-ew/1863230.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.